1. Home
  2. CGEN vs NHS Comparison

CGEN vs NHS Comparison

Compare CGEN & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.74

Market Cap

220.7M

Sector

Health Care

ML Signal

HOLD

Logo Neuberger Berman High Yield Strategies Fund

NHS

Neuberger Berman High Yield Strategies Fund

HOLD

Current Price

$7.59

Market Cap

230.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEN
NHS
Founded
1993
2003
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
220.7M
230.7M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
CGEN
NHS
Price
$1.74
$7.59
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
568.8K
111.8K
Earning Date
03-03-2026
01-01-0001
Dividend Yield
N/A
13.44%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,903,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$164.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.13
$6.95
52 Week High
$2.66
$9.17

Technical Indicators

Market Signals
Indicator
CGEN
NHS
Relative Strength Index (RSI) 42.09 65.17
Support Level $2.04 $7.54
Resistance Level $2.08 $7.64
Average True Range (ATR) 0.12 0.06
MACD -0.05 0.01
Stochastic Oscillator 1.00 85.37

Price Performance

Historical Comparison
CGEN
NHS

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About NHS Neuberger Berman High Yield Strategies Fund

Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.

Share on Social Networks: